Last updated 2026-09-04
- Went public on NASDAQ (CGEN), Aug 2000
- Raised $200M Follow-on PO, Oct 2016
- Raised $200M Follow-on PO, Sep 2014
Total raised
$804.4M
Stage
Public
Founded
1993
Headcount
77
HQ
Holon, Israel
Sector
Health Tech & Life Sciences
About
Compugen is a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery. The company has been at the forefront of decoding cancer biology with its AI-powered predictive computational discovery platform, Unigen™. Unigen™ combines deep scientific knowledge, AI/ML predictive algorithms, and a cloud-based, technology-agnostic platform integrating various biological data. The outcomes from preclinical and clinical trials enrich its proprietary knowledgebase to discover additional novel drug targets and further understand complex biology. To date, Unigen™ has yielded multiple novel immuno-oncology drug targets, potential first or best-in-class clinical stage immuno-oncology programs, validating partnerships with multiple pharmaceutical companies, and undisclosed programs in its early-stage pipeline.
Funding history · 11 rounds · $804.4M total
13 events/rounds · $804.4M Total Funding: $35.4M in Private Equity, $769.0M in Public Equity
Jan 2023
Follow-on PO
$50.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2020
Follow-on PO
$75.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jun 2018
Follow-on PO
$21.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Oct 2016
Follow-on PO
$200.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Sep 2014
Follow-on PO
$200.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2014
Follow-on PO
$63.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2013
Follow-on PO
$100.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2011
Follow-on PO
$40.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Oct 2009
Follow-on PO
$20.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jan 2002
Jul 2000
B Round
$35.4M
tracxn.com
Headcount over time
77 employees (2026-09) · 1 point
Offices
Holon, Israel · HQ / main office
Show all offices (1 more)
- South San Francisco, United States
Q&A
- What is Compugen's primary focus?
- Compugen is a clinical-stage cancer immunotherapy company that uses an AI-powered predictive computational discovery platform to identify novel drug targets and develop cancer immunotherapies.
- When did Compugen go public on NASDAQ?
- Compugen went public on NASDAQ in August 2000.
- How many employees does Compugen currently have?
- Compugen has 51-200 employees.
- What was the amount raised in Compugen's Public Offering in January 2023?
- In January 2023, Compugen raised $50,000,000 through a Public Offering.
- What was a significant recent development for Compugen regarding a milestone payment?
- In May 2024, Compugen was set to receive a milestone payment triggered by the dosing of the first patient in the second Phase 3 trial evaluating Rilvegostomig.
- What was a key partnership announcement for Compugen in December 2023?
- In December 2023, Gilead and Compugen announced an exclusive license agreement for a novel pre-clinical immunotherapy program.
- What was a recent intellectual property expansion for Compugen?
- In November 2024, Compugen expanded its intellectual property portfolio with a new U.S. patent covering the triple combination use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG antibodies.
- What was a recent clinical trial update for Compugen's COM701 program?
- In July 2025, Compugen announced the first patient was dosed in the COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer.
- What was a significant financial transaction for Compugen in December 2025?
- In December 2025, Compugen monetized a portion of its Rilvegostomig future royalties to AstraZeneca for up to $90 million.
Team · 7
Eran Ophir
President & CEO
Anat Cohen-Dayag
Executive Chair of the Board of Directors
David Silberman
Chief Financial Officer
Michelle Mahler
Chief Medical Officer
Pierre Ferre
Chief Operating Officer
Sharon Kredo-Russo
VP, Head of Research & Development
Zurit Levine
Senior Vice President, Technology Innovation
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Highlights
1 Patents
Tags
immunologyoncologybiotechnologybioinformaticsantibodiesdrug-discoveryproteinspharmaceuticalsimmunotherapycancer-therapyautoimmune-diseasespatientspharma-companiescancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Legal name | Compugen Ltd. |
|---|---|
| Founded | 1993 |
| Employees (exact) | 77 |
| Offices | South San Francisco |
| Market cap | $143.2M |
| Status reason | Public on NASDAQ on Aug, 2000;Public on TASE on Jan, 2002; |
| Wikidata QID | Q5157220 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2000-08 | NASDAQ | CGEN | |
| Listing | 2002-01 | TASE | CGEN |
Radar intelligence
Open jobs — comeet
| Total open | 2 |
|---|---|
| Remote | 0 |
| By department | Drug Discovery and Validation (1), Immuno-Oncology Research (1) |
| By location | Israel (2) |
| Title | Location | Department |
|---|---|---|
| Senior Scientist, Antibody Engineering & Discovery | Israel | Drug Discovery and Validation |
| Research Lab Technician | Israel | Immuno-Oncology Research |
Patents
| EPO | 156 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | cgen.com |
|---|
Wikidata
| QID | Q5157220 |
|---|
Certificate / subdomain footprint
| Subdomains | 20 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 511779639 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1993-02-10 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 1998 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הרוקמים 26 חולון |